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Background-—The independent prognostic impact of diabetes mellitus (DM) and prediabetes mellitus (pre-DM) on survival
outcomes in patients with chronic heart failure has been investigated in observational registries and randomized, clinical trials, but
the results have been often inconclusive or conﬂicting. We examined the independent prognostic impact of DM and pre-DM on
survival outcomes in the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufﬁcienza Cardiaca-Heart Failure) trial.
Methods and Results-—We assessed the risk of all-cause death and the composite of all-cause death or cardiovascular
hospitalization over a median follow-up period of 3.9 years among the 6935 chronic heart failure participants of the GISSI-HF trial,
who were stratiﬁed by presence of DM (n=2852), pre-DM (n=2013), and non-DM (n=2070) at baseline. Compared with non-DM
patients, those with DM had remarkably higher incidence rates of all-cause death (34.5% versus 24.6%) and the composite end
point (63.6% versus 54.7%). Conversely, both event rates were similar between non-DM patients and those with pre-DM. Cox
regression analysis showed that DM, but not pre-DM, was associated with an increased risk of all-cause death (adjusted hazard
ratio, 1.43; 95% CI, 1.28–1.60) and of the composite end point (adjusted hazard ratio, 1.23; 95% CI, 1.13–1.32), independently of
established risk factors. In the DM subgroup, higher hemoglobin A1c was also independently associated with increased risk of both
study outcomes (all-cause death: adjusted hazard ratio, 1.21; 95% CI, 1.02–1.43; and composite end point: adjusted hazard ratio,
1.14; 95% CI, 1.01–1.29, respectively).
Conclusions-—Presence of DM was independently associated with poor long-term survival outcomes in patients with chronic heart
failure.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT00336336. ( J Am Heart Assoc. 2017;6:
e005156. DOI: 10.1161/JAHA.116.005156.)
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C hronic heart failure (CHF) is a progressive, complexclinical syndrome characterized by considerably high
rates of morbidity and mortality and results as a common
aftermath of a wide range of cardiovascular damages, alone or
in combination with other comorbid conditions, such as
diabetes mellitus (DM), leading to early death.1–6 The
prevalence of DM in patients with heart failure (HF) is
extremely high (occurring in up to 40–45% of these
From the Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona,
Italy (M.D., G. Targher); Division of Cardiology, Istituti Clinici Scientiﬁci Maugeri, IRCCS, Veruno, Italy (P.L.T.); ANMCO Research Center, Florence, Italy (D.L., L.G.,
A.P.M.); Department of Cardiology, Santa Maria degli Angeli Hospital, Pordenone, Italy (G.L.N.); Therapeutic Science and Strategy Unit (TSSU), Quintiles, Milan, Italy
(R.M.); Department of Cardiovascular Research, IRCCS-Istituto di Ricerche Famacologiche Mario Negri, Milan, Italy (G. Tognoni, R.L.); Division of Cardiology, Ospedale
Valdichiana Santa Margherita, Cortona, Italy (F.C.); Maria Cecilia Hospital, GVM Care & Research, Ettore Sansavini Health Science Foundation, Cotignola, Italy (L.T.).
*Dr Dauriz and Dr Targher contributed equally to the manuscript.
**A complete list of the GISSI-HF Investigators can be found in the Appendix at the end of the manuscript.
Correspondence to: Aldo Pietro Maggioni, MD, ANMCO Research Centre, Via La Marmora, 34, 50121 Firenze, Italy. E-mail: maggioni@anmco.it
Received November 25, 2016; accepted May 5, 2017.
ª 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for
commercial purposes.
DOI: 10.1161/JAHA.116.005156 Journal of the American Heart Association 1
ORIGINAL RESEARCH
D
ow
nloaded from
 http://ahajournals.org by on July 17, 2019
patients).7,8 Not surprisingly, the burden of morbidity and
mortality associated with CHF and DM represents, to date, a
major challenge for the prospective sustainability of contem-
porary healthcare systems.8–11
The most recent European Society of Cardiology guidelines
have embraced the importance of a multidisciplinary team-
based approach for the management of DM in patients with
acute or CHF.12 However, despite the existence of a
signiﬁcant association between hyperglycemia and adverse
clinical outcomes in patients with HF,9,13–15 no recommen-
dations to identify speciﬁc glycemic goals or high-risk patient
groups have been provided so far, mainly because of the lack
of compelling evidence on the beneﬁt of universally achieving
a strict glycemic control.16 Additionally, randomized, clinical
trials that have explored the cardiovascular safety of the
newer hypoglycemic drugs did not ﬁnd any clear beneﬁt on
the risk of HF in patients with DM at high cardiovascular risk,
except for opposite effects of empagliﬂozin (positive) and
saxagliptin (negative) on the risk of HF hospitalization.17–19
Currently, there is intense debate about the independent
prognostic impact of DM on the risk of long-term survival
outcomes in patients with acute HF or CHF. For example, in a
recent analysis of the Long-Term EURObservational Research
Programme Heart Failure Registry, we found that the
presence of DM was independently associated with an
increased risk of in-hospital death, 1-year all-cause death,
and 1-year HF re-hospitalizations in patients hospitalized for
acute HF, thus supporting the importance of an early and
appropriate management of DM in this patient population.10
In contrast, Kosiborod et al did not ﬁnd any signiﬁcant
association between the presence of pre-existing DM (or
elevated glucose levels at hospital admission) and the risk of
30-day or 1-year mortality in a large, nationally representative
cohort of US elderly patients hospitalized with HF.20
Notably, a number of other observational registries and
randomized, clinical trials that explored the prognostic role of
DM per se on survival outcomes in patients with HF have
often reported inconclusive or conﬂicting results,21–28 sug-
gesting the need for further studies. In addition, very few
studies also explored the independent prognostic role of pre-
DM on survival outcomes in this particularly high-risk patient
population. Clearly, these issues warrant further investigation.
Thus, in a post-hoc analysis of the GISSI-HF (Gruppo
Italiano per lo Studio della Sopravvivenza nella Insufﬁcienza
Cardiaca-Heart Failure) trial, we aimed at investigating
whether the presence of DM and pre-DM independently
affected the long-term survival outcomes in a large cohort of
ambulatory patients with CHF.
Methods
Study Population and Design
The rationale and thestudydesignof theGISSI-HF trial havebeen
thoroughly presented elsewhere in previous publications,29,30
and the registered study protocol is available online at https://
clinicaltrials.gov (ClinicalTrials.gov Identiﬁer: NCT00336336).
Brieﬂy, the GISSI-HF trial started in 2002 as a pragmatic,
double-blind, placebo-controlled, nation-wide, multicenter
study in 326 cardiology and 31 internal medicine centers
with the speciﬁc aim of testing with a nested design the
efﬁcacy and safety of 2 different drugs (rosuvastatin 10 mg
daily or n-3 polyunsaturated fatty acids [PUFAs] 1 g daily) in
outpatients with CHF. Upon its completion in 2008, the trial
enrolled 6975 patients aged ≥18 years with clinical evidence
of HF of any cause that was classiﬁed according to the
European Society of Cardiology guidelines as New York Heart
Association (NYHA) functional class II to IV, provided that they
had had their left ventricular ejection fraction (LVEF)
measured within 3 months before the study enrollment.
When LVEF was greater than 40%, the patient had to have
been admitted to the hospital for HF at least once in the
preceding year to meet the inclusion criteria.
Major exclusion criteria included: known hypersensitivity
to the study treatments or ongoing treatment with the study
drugs; presence of any noncardiac comorbidity that was
unlikely to be compatible with sufﬁciently long follow-up (eg,
Clinical Perspective
What is New?
• Presently, there is intense debate about the independent
prognostic impact of diabetes mellitus on the risk of long-
term survival outcomes in patients with chronic heart
failure.
• The added value of the GISSI-HF (Gruppo Italiano per lo
Studio della Sopravvivenza nella Insufﬁcienza Cardiaca-
Heart Failure) trial to existing literature is that it provides
clear evidence on the independent prognostic role of
diabetes mellitus on the risk of all-cause death and
cardiovascular hospitalization in a cohort of nearly 6900
ambulatory patients with chronic heart failure followed-up
for a median of 3.9 years.
• Another added value of the GISSI-HF trial is the ﬁnding of a
signiﬁcant association between elevated hemoglobin A1c
levels and the risk of all-cause death and cardiovascular
hospitalization among patients with diabetes mellitus,
independent of multiple established risk factors.
What are the Clinical Implications?
• Collectively, these ﬁndings further reinforce the clinical
importance for a more patient-centered, coordinated, and
multidisciplinary team-based approach to the management
of diabetes mellitus in patients with chronic heart failure.
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cancer); acute coronary syndrome or revascularization proce-
dures within 1 month; planned cardiovascular surgery,
expected to be performed within 3 months after randomiza-
tion; signiﬁcant liver diseases; serum creatinine concentra-
tions >2.5 mg/dL; serum aminotransferase concentrations
>1.5 times the upper normal limit; serum creatinine phos-
phokinase concentrations above the upper normal limit; and
pregnant or lactating women or women of childbearing
potential, who were not on contraceptive protection. The
exact number of patients excluded for each condition was not
systematically recorded in each participating center.
Two independent randomization schemes were then
employed to test against placebo the effect of either n-3
PUFA or rosuvastatin on the occurrence of 2 co-primary
prespeciﬁed study end points over a median follow-up period
of 3.9 years: (1) all-cause death and (2) the composite of all-
cause death or cardiovascular hospitalization. All study end
points were adjudicated blindly by an ad-hoc committee on
the basis of preagreed deﬁnitions and procedures. All reports
included a narrative summary with supporting documentation
for every event (eg, clinical records, death certiﬁcates, and
any other relevant documentation).
The GISSI-HF trial was approved by each local institutional
review board of all the participating centers. A written
informed consent was obtained from each study participant
before the study enrollment.
The primary results of the GISSI-HF trial have been already
published and demonstrated a small beneﬁcial advantage only
by n-3 PUFA treatment, irrespective of pre-existing DM.29,30
The results herein presented pertain to a secondary
analysis on 6935 participants (99.5% of total) from the
GISSI-HF trial, who had available data on previous history of
DM as well as fasting plasma glucose or hemoglobin A1c
measurements at the study entry.
Diagnosis of DM, Pre-DM, and Other Clinical and
Laboratory Data
According to widely accepted diagnostic criteria,31,32 the
presence of known or previously undiagnosed DM was deﬁned
as self-reported physician diagnosis of diabetes mellitus,
current use of hypoglycemic drugs, a fasting plasma glucose
level ≥7.0 mmol/L (≥126 mg/dL), or a hemoglobin A1c
(HbA1c) level ≥6.5% (≥48 mmol/mol). Pre-DM was deﬁned
according to the presence of HbA1c from 6% (≥42 mmol/mol)
to <6.5% (<47 mmol/mol) and/or fasting plasma glucose
levels from 5.6 to 6.9 mmol/L (100–125 mg/dL). Patients
without DM were deﬁned as those without a previous history of
DM and with a fasting plasma glucose level <5.6 mmol/L
(<100 mg/dL) and HbA1c <6% (<42 mmol/mol).
Serum lipids, HbA1c, and other biochemical blood mea-
surements were determined in all participants after an
overnight fasting using standard laboratory procedures. The
measurement of HbA1c was available for 5698 (82.2%) of
6935 patients. Body mass index was calculated by dividing
patients’ weight in kilograms by their height in squared
meters. Patients were considered to have hypertension if their
blood pressure was ≥140/90 mm Hg or if they were taking
any antihypertensive drugs. The glomerular ﬁltration rate was
estimated by the 4-variable Modiﬁcation of Diet in Renal
Disease study equation.33 The left ventricular diameter, wall
thickness, and ejection fraction were assessed by conven-
tional transthoracic echocardiography according to interna-
tional standard criteria.
Statistical Analysis
Categorical variables are presented as percentages, whereas
continuous variables are presented as meansSD. Categor-
ical variables were compared by the chi-square test. The 1-
way ANOVA was applied to compare all continuous variables
across participants with different categories of glucose
regulation, with the only exception of serum creatinine,
glomerular ﬁltration rate , and triglycerides, which were
analyzed by the Kruskal–Wallis test, being not normally
distributed. Multiple comparisons between patient groups
(DM patients versus pre-DM patients; DM patients versus
non-DM patients; and pre-DM patients versus non-DM
patients) were also performed using the Bonferroni correction.
Two multivariable Cox regression models (model 1: unad-
justed; model 2: adjusted for age, sex, Body mass index, heart
rate, systolic blood pressure, serum creatinine and cholesterol
levels, smoking, hypertension, atrial ﬁbrillation, chronic
obstructive pulmonary disease, NYHA functional class, HF
etiology, and LVEF) were applied, with non-DM patients as the
reference category, to estimate the risk that the presence of
DM and pre-DM carried in terms of all-cause death and the
composite end point inclusive of all-cause death or cardio-
vascular hospitalization. Covariates included in multivariable
regression models were chosen as potential confounding
factors on the basis of their signiﬁcance in univariate
regression analysis or on the basis of their biological
plausibility. Because the risk of all-cause death or admission
to hospital for cardiac reasons was affected by the study
treatments (n-3 PUFAs or rosuvastatin) in all predeﬁned
subgroups in much the same way, with no evidence of
heterogeneity of treatment effect,29,30 we did not include the
study treatment or placebo among the covariates. The same
Cox regression models were also performed after excluding
patients with baseline LVEF >40% from analysis.
In order to test whether a poorer quality of glycemic
control at baseline was associated with a higher risk of
adverse clinical outcomes over the follow-up period, we
performed similar Cox regression analyses in the subgroup of
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patients with available HbA1c measurements at baseline by
simultaneously stratifying these patients according to their
DM status and HbA1c tertiles. In order to obtain subgroups of
comparable sample size, we separately examined the sub-
group of patients with DM (n=2466) and the combined
subgroup of patients with pre-DM and without DM (n=3232),
by taking the ﬁrst tertile of HbA1c within each subgroup as
the reference category. Kaplan–Meier curves were also
produced for both co-primary study end points and compared
among the mentioned groups by the log-rank test.
Statistical signiﬁcance was set at 2-sided P value of 0.05.
All statistical tests were performed with SAS software (version
9.2; SAS Institute Inc, Cary, NC) at the GISSI-HF coordinating
center (Florence, Italy).
Results
The study cohort comprised a total of 6935 (78.3% men)
ambulatory patients with CHF. The age range was spanning
from a minimum of 18 years to a maximum of 97 years, with a
meanSD of 67.211 years; around 42% of patients were
older than 70 years. The mean LVEF of the entire cohort was
33.18%; 9.4% (n=652) of patients had a baseline LVEF >40%.
Prevalence of DM in the study cohort was high (n=2852;
41%); 69.2% (n=1974) of these patients had previously known
DM (ie, self-reported history or use of hypoglycemic drugs),
whereas the remaining 878 (30.8%) patients had previously
undiagnosed DM. Among those with previously undiagnosed
DM, 568 (64.7%) patients had an HbA1c ≥6.5% (of whom 151
also had a fasting glucose level ≥7.0 mmol/L), whereas the
remaining 310 had a fasting glucose level ≥7.0 mmol/L (but
with an HbA1c level <6.5%).
As shown in Table 1, compared with those with pre-DM or
without DM, patients with DM were older (though the
percentage of those aged ≥70 years was comparable among
the three groups of patients), more likely to be female, had a
higher number of comorbid conditions, such as obesity,
hypertension, ischemic etiology of HF, chronic obstructive
pulmonary disease, chronic kidney disease, and higher NYHA
functional classes. Moreover, they also had (slightly) higher
LVEF and were more likely to be treated with lipid-lowering
and antiplatelet drugs, nitrates, digitalis, diuretics, aldos-
terone-antagonists, and calcium-channel blockers, but less
often treated with amiodarone and beta-blockers. Random-
ized drug treatments started over the trial (n-3 PUFAs or
rosuvastatin) were substantially comparable among the 3
groups of patients, except for a (slightly) lower percentage of
non-DM patients randomized to rosuvastatin. Table 1 also
shows P values for multiple comparisons between patient
groups by using the Bonferroni correction.
Over the follow-up period of the trial (median duration,
3.9 years; interquartile range, 3.0–4.5 years), there were
1958 (28.2%) total deaths and 3302 (47.6%) patients
admitted to the hospital because of cardiovascular reasons.
The combined end point of all-cause death or cardiovascular
hospitalization occurred in 4011 (57.8%) patients. Among the
speciﬁc causes of death, 75.1% (n=1471) were cardiovascular
(mainly attributed to worsening HF or sudden cardiac death),
21.1% (n=413) were noncardiovascular (mainly attributed to
malignancy or acute infections), and 3.8% (n=74) were
unknown. As shown in Table 2, no signiﬁcant differences
were found in the speciﬁc causes of death among patients
stratiﬁed by their glycemic status at baseline (P=0.69).
As shown in Figure 1, patients with DM had remarkably
higher (P<0.0001) cumulative incidence rates of all-cause
death (n=984; 34.5%) compared with patients with pre-DM
(n=465; 23.1%) or those without DM (n=509; 24.6%),
respectively. The same applies to the co-primary outcome of
all-cause death or cardiovascular hospitalization: Of 4011
(57.8%) patients with the combined end point over the follow-
up, the event rates were higher in patients with DM (n=1814;
63.6%) than in those with pre-DM (n=1064; 52.9%) and in
those without DM (n=1133; 54.7%). Moreover, patients with
DM also had signiﬁcantly higher rates of cardiovascular
hospitalization alone (n=1481; 51.9%) compared with those
with pre-DM (n=887; 44.1%) and those without DM (n=934;
45.1%), respectively.
The visual inspection of the Kaplan–Meier curves for the
rates of all-cause death (Figure 2), and the composite of all-
cause death or cardiovascular hospitalization (Figure 3)
shows the data just reported, also substantially higher
incidence rates of both clinical end points in patients with
DM compared with pre-DM and non-DM patients over the
follow-up period (P<0.0001, by the log-rank test). Conversely,
no signiﬁcant differences in these clinical outcomes were
found between patients with pre-DM and those without DM.
Table 3 shows that patients with DM had an 1.5-fold
increased risk of all-cause death and a 1.3-fold increased risk
for the composite of all-cause death or cardiovascular
hospitalization compared with patients without DM. The
robustness of these associations did hold in Cox regression
analysis even after adjustment for multiple clinical risk factors
and potential confounding variables, with an adjusted hazard
ratio of 1.43 (95% CI, 1.28–1.60; P<0.0001) for all-cause
death and 1.23 (95% CI, 1.13–1.32; P<0.0001) for the
composite end point, respectively. Among the covariates
included in the fully adjusted regression model, the following
also showed an independent association with the risk of both
clinical end points: older age, lower body mass index, lower
systolic blood pressure, lower total cholesterol, higher serum
creatinine, presence of atrial ﬁbrillation/ﬂutter, previous
chronic obstructive pulmonary disease, ischemic etiology of
HF, higher NYHA functional class, and lower LVEF. Almost
identical results were found when the study treatments (n-3
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Table 1. Baseline Clinical and Biochemical Characteristics of Patients With Chronic HF Enrolled in the GISSI-HF Trial, Stratiﬁed by
Glycemic Status at Baseline
DM Patients
(n=2852)
Pre-DM Patients
(n=2013)
Non-DM Patients
(n=2070) P Value
Males, % 77* 81 78 <0.01†
Age, y 6810* 6711 6612‡ <0.0001†
Age ≥70 y, % 43 42 42 0.90
NYHA class, III to IV, % 42* 33 33‡ <0.0001†
BMI, kg/m2 285* 274§ 264‡ <0.0001†
BMI ≥30 kg/m2, % 29* 21§ 15‡ <0.0001†
Systolic blood pressure, mm Hg 12818* 12617§ 12418‡ <0.0001†
Diastolic blood pressure, mm Hg 7710 7710 7610‡ <0.01†
Heart rate, bpm 7413* 7213 7113‡ <0.001†
Diabetes mellitus treatment at randomization, %
Insulin 19   NA
Oral drugs only 39   NA
Diet only 42   NA
Hemoglobin, g/dL 13.61.7* 13.91.6§ 13.71.6‡ <0.0001†
Total cholesterol, mg/dL 18844* 19543§ 19141‡ <0.0001†
Triglycerides, mg/dL 161104* 14287§ 13179‡ <0.0001†
Fasting glucose, mmol/L 8.333.2* 5.830.6§ 4.890.4‡ <0.0001†
Hemoglobin A1c, %k 7.21.6* 5.70.6§ 5.20.6‡ <0.0001†
Hypertension, % 63* 52§ 46‡ <0.0001†
Current smoking, % 13 15 15 0.061
Lipid-lowering medications at randomization, % 25 23 20‡ <0.001†
Cardiovascular medications at randomization, %
ACE-I or ARBs 94 93 94 0.15
Beta-blockers 62* 67 66 0.001†
Aldosterone-antagonists 42 40§ 36‡ <0.001†
Diuretics 93* 88 87‡ <0.001†
Digitalis 39* 35 36 0.01†
CCBs 13* 9 8‡ <0.0001†
Antiplatelets 60* 54 54‡ <0.0001†
Anticoagulants 28 30 29 0.60
Nitrates 40* 33 32‡ <0.0001†
Amiodarone 18 20 22‡ <0.001†
Randomized drug treatment, %
n-3 PUFAs 50 50 51 0.91
Rosuvastatin¶ 52 50 47‡ 0.03†
Creatinine, mg/dL 1.30.5* 1.20.5§ 1.20.4‡ <0.0001†
eGFRMDRD, mL/min per 1.73 m
2 65.624.9* 69.321.6 70.622.3‡ <0.0001†
LVEF, % 33.38.6 33.28.5 32.78.3‡ 0.03†
LVEF >40%, % 11 9 8‡ <0.01†
HF etiology, ischemic, % 56* 46 45‡ <0.0001†
Atrial fibrillation/flutter, % 17 17 15 0.07
Continued
DOI: 10.1161/JAHA.116.005156 Journal of the American Heart Association 5
Chronic Heart Failure and Diabetes Dauriz et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on July 17, 2019
PUFAs or rosuvastatin) were included as additional covariates
in these multivariable regression models; in all models, the
adjusted hazard ratios for both pre-DM status and DM status
remained unchanged. Moreover, both study treatments were
not signiﬁcantly associated with the risk of all-cause death
and the composite of all-cause death or cardiovascular
hospitalization in any of these regression models (data not
shown).
Table 4 shows the results of Cox regression analysis of
all-cause death alone or in combination with cardiovascular
hospitalization in patients with CHF after excluding those
with LVEF >40% at the study entry (n=652). Also in this
case, the results remained essentially unchanged showing
that the presence of DM, but not pre-DM, was signiﬁcantly
associated with an increased risk of all-cause death and of
the composite end point after adjusting for potential
confounding variables.
Table 5 shows the change in the risk of study outcomes
across worsening classes of glycemic control in the subgroup
of CHF patients (n=5698) with available HbA1c measure-
ments at baseline. Compared with the combined group of pre-
DM and non-DM patients, those with DM had always higher
rates per 100 patient-years for both study outcomes at each
level of HbA1c. In particular, the event rates of all-cause death
across HbA1c tertiles were almost double in patients with DM
compared with those in the combined group of pre-DM and
non-DM patients. Moreover, in the DM group, the association
between glycemic control and the risk of clinical outcomes
was statistically signiﬁcant in the third tertile of HbA1c
(HbA1c >7.5%) after adjustment for multiple potential
confounding variables, with an adjusted hazard ratio of 1.21
(95% CI, 1.02–1.43) for all-cause death and 1.14 (95% CI,
1.01–1.29) for the combined end point, respectively.
Discussion
The main ﬁndings of this post-hoc analysis of the GISSI-HF
trial are as follows: (1) pre-DM and DM were 2 extremely
common pathologic conditions in ambulatory patients with
CHF (29% and 41%, respectively); (2) the presence of known
or previously undiagnosed DM was signiﬁcantly associated
with a higher risk of both all-cause death or cardiovascular
hospitalization, whereas the presence of pre-DM was not;
(3) the association between DM and the risk of long-term
clinical outcomes remained signiﬁcant even after adjustment
for multiple established risk factors and potential confounding
variables; and (4) in patients with DM, the risk of long-term
clinical outcomes was independently associated with poor
glycemic control (as measured by HbA1c levels).
Table 1. Continued
DM Patients
(n=2852)
Pre-DM Patients
(n=2013)
Non-DM Patients
(n=2070) P Value
COPD, % 25* 21 19‡ <0.0001†
Previous neoplasm, % 3 4 4 0.35
Pacemaker, % 13 13 12 0.60
Previous ICD, % 6 7 9‡ 0.014†
Previous IHD, % 52* 44 42‡ <0.0001†
Previous stroke, % 6 5 4‡ <0.005†
Cohort size, n=6935, data presented as meansSD or percentages. One-way ANOVA was applied to all continuous variables with the only exception of serum creatinine, triglycerides, and
eGFR, which were analyzed by the Kruskal–Wallis test. ARBs indicates angiotensin receptor blockers; BMI, body mass index; CCBs, calcium-channel blockers; COPD, chronic obstructive
pulmonary disease; DM, diabetes mellitus; eGFRMDRD, glomerular ﬁltration rate estimated according to the Modiﬁcation of Diet in Renal Disease (MDRD) study equation; GISSI-HF, Gruppo
Italiano per lo Studio della Sopravvivenza nella Insufﬁcienza Cardiaca-Heart Failure; HF, heart failure; ICD, implantable cardioverter defribrillator; IHD, ischemic heart disease (ie, composite
end point of myocardial infarction or angina pectoris); LVEF, left ventricular ejection fraction; NA, not applicable; NYHA, New York Heart Association; PUFAs, polyunsaturated fatty acids.
*P<0.017 for comparison between DM patients and pre-DM patients (by the Bonferroni correction).
†
Two-tailed P<0.05 for comparison among DM patients, pre-DM patients and non-DM patients (1-way ANOVA or Kruskal-Wallis).
‡
P<0.017 for comparison between DM patients and non-DM patients (by the Bonferroni correction).
§
P<0.017 for comparison between pre-DM patients and non-DM patients (by the Bonferroni correction).
k
Hemoglobin A1c measurements were available for n=5698 patients.
¶
Percentages evaluated on 4546 patients randomized to rosuvastatin/placebo.
Table 2. Speciﬁc Causes of Death in Patients With Chronic
HF Enrolled in the GISSI-HF Trial, Who Were Stratiﬁed by Their
Glycemic Status at Baseline (ie, Patients With DM, Patients
With Pre-DM, and Those Without Diabetes Mellitus [Non-DM],
Respectively)
Causes of Death
No. of Died
Patients With
DM (n=984)
No. of Died
Patients With
Pre-DM (n=465)
No. of Died
Patients Without
DM (n=509)
Cardiovascular 742 (75.4%) 356 (76.6%) 373 (73.3%)
Noncardiovascular 202 (20.5%) 93 (20.0%) 118 (23.2%)
Unknown 40 (4.1%) 16 (3.4%) 18 (3.5%)
GISSI-HF indicates Gruppo Italiano per lo Studio della Sopravvivenza nella Insufﬁcienza
Cardiaca-Heart Failure; HF, heart failure.
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The independent prognostic impact of DM on survival
outcomes in patients with CHF has been investigated in
observational registries and randomized, clinical trials, but the
results have been often inconclusive or conﬂicting.4,9,20–
24,27,28,34 Similarly, few studies have investigated the preva-
lence of pre-DM in patients with CHF and even fewer its
clinical consequences (and with conﬂicting ﬁndings).9,14,20,24
In particular, the results of the GISSI-HF trial contrast with
those from other previously published clinical trials, including
the SOLVD (Studies Of Left Ventricular Dysfunction) Preven-
tion and Treatment trial, the DIG (Digitalis Investigation
Group) trial, and the BEST (Beta-Blocker Evaluation of Survival)
trial,21–23 which have reported that the independent prog-
nostic impact of DM, if any, on survival outcomes in patients
with advanced HF might be conﬁned only to those with
ischemic cardiomyopathy. The OPTIMIZE-HF (Organized Pro-
gram to Initiate Lifesaving Treatment in Hospitalized Patients
with HF) registry also showed that patients with coexistent HF
and DM had similar rates of in-hospital and 3-month
postdischarge survival outcomes compared with those with-
out DM.27 Moreover, Kosiborod et al did not ﬁnd any
signiﬁcant association between DM and 1-year all-cause
mortality in a nationally representative cohort of 50 532 US
elderly patients hospitalized with HF.20 More recently, in the
IN-HF (Italian Network on Heart Failure) Outcome registry
cohort of nearly 1800 patients hospitalized with acute HF, we
found that patients with previously known DM had signiﬁ-
cantly higher in-hospital death rates, but similar postdischarge
1-year death rates compared with those without DM.26
However, the ﬁndings of the GISSI-HF trial conﬁrm and
extend the results of other large, randomized, clinical trials,
supporting the existence of a signiﬁcant and independent
association between DM and poor long-term clinical outcomes
in patients with CHF. For instance, the CHARM (Candesartan in
Heart Failure: Assessment of Reduction in Mortality and
morbidity) trial, involving nearly 7600 patients with symp-
tomatic CHF who were followed-up for a median period of
3 years, reported that pre-existing DM was a powerful
predictor of all-cause death and of a composite of cardiovas-
cular death or HF hospitalization.34 Furthermore, a meta-
analysis of 30 cohort studies (6 of which were randomized,
clinical trials) that included individual data on nearly 39 000
patients with CHF has shown that the presence of DMpredicted
independently the risk of all-cause death over a median follow-
up period of 2.5 years.4 Recently, a post-hoc analysis of the
PARADIGM-HF (Prospective Comparison of ARNI With ACEI to
Determine Impact on Global Mortality and Morbidity in Heart
Failure) trial reported that both DM and pre-DM were indepen-
dently associated with an increased risk of the composite of
cardiovascular death or HF hospitalization in 8399CHF patients
with LVEF <35%, who were randomly assigned to sacubutril/
valsartan treatment or enalapril and followed-up for 3 years.24
Interestingly, in agreement with some previous stud-
ies,34,35 we found that having a diagnosis of DM, a worsening
of NYHA class and a previous history of chronic obstructive
pulmonary disease each accounted by a comparable order of
magnitude for the higher long-term risk of all-cause death or
cardiovascular hospitalization observed in patients with HF.
In contrast to the ﬁndings of the PARADIGM-HF trial, in this
study we did not ﬁnd a mortality risk continuum across the
entire range of glucose regulation categories, given that
patients with pre-DM did not show signiﬁcantly higher
incidence rates of all-cause death or cardiovascular hospital-
ization compared with those without DM over the follow-up.
This might be partly attributed to differences both in the study
design and in the clinical characteristics of patients enrolled
in the GISSI-HF trial (which was essentially a pragmatic, all-
comer–oriented clinical trial) and in the PARADIGM-HF trial
(which adopted very strict enrollment criteria, including the
presence of LVEF <35% and the study drug tolerability in a
long run-in observational period). However, our ﬁndings are
also consistent with those reported by Goode et al,14 who did
not observe any signiﬁcant increase in the risk of all-cause
Figure 1. Cumulative incidence rates of all-cause death and
cardiovascular hospitalization in patients with chronic heart
failure from the GISSI-HF (Gruppo Italiano per lo Studio della
Sopravvivenza nella Insufﬁcienza Cardiaca-Heart Failure) trial, who
were stratiﬁed by baseline glycemic status. The panel shows the
occurrence of all-cause death and cardiovascular hospitalization,
singly or in combination, in patients with diabetes mellitus (DM;
n=2852), patients with prediabetes mellitus (pre-DM; n=2013),
and those without diabetes mellitus (non-DM; n=2070), who were
followed-up for a median of 3.9 years.
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Figure 2. Kaplan–Meier curves for time to all-cause death among the 3 groups of patients with chronic
heart failure, who were stratiﬁed by baseline glycemic status.
Figure 3. Kaplan–Meier curves for time to all-cause death or cardiovascular hospitalization among the 3
groups of patients with chronic heart failure, who were stratiﬁed by baseline glycemic status. DM indicates
diabetes mellitus.
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death among nondiabetic CHF patients with a HbA1c level
less than 6.5%.
Collectively, we believe that the added value of the GISSI-HF
trial to existing literature is that it provides clear evidence on the
prognostic role of DM per se on the risk of long-term survival
outcomes in a large cohort of outpatients with CHF. Although
clinical trial databases, like this, have limitations of being
selective compared with general practice, they provide the
advantage of systematic data collection and complete high-
quality follow-up. Moreover, all study outcomes of the GISSI-HF
trial were prospectively collected and blindly adjudicated.
Another added value of the GISSI-HF trial is the ﬁnding of a
signiﬁcant association between poor glycemic control (as
measured by HbA1c level that was available in most of our
patients at baseline) and the risk of all-cause death and
cardiovascular hospitalization in patients with DM, indepen-
dent of multiple clinical risk factors and potential con-
founders. Therefore, our ﬁndings further reinforce the clinical
importance for a patient-centered, team-based approach to
the management of patients with coexistent HF and DM.
However, our study has some important limitations that
should be kept in mind: (1) As mentioned previously, this is a
post-hoc analysis of the GISSI-HF trial that was not primarily
undertaken to examine the prognostic impact of DM and pre-
DM on long-term survival outcomes of patients with CHF;
(2) despite that both fasting plasma glucose and HbA1c levels
were available for the majority of the GISSI-HF participants,
the diagnosis of newly diagnosed DM was based on HbA1c
and/or with a single-point fasting glucose measurement,
without further systematic conﬁrmation by a second deter-
mination on a separate day; however, this is an intrinsic
limitation of all large, observational registries and randomized,
clinical trials, in which the conﬁrmation of DM diagnosis, on at
least 2 separate occasions, in patients with newly diagnosed
DM has been never made; (3) the GISSI-HF participants were
not necessarily representative of the garden variety of
ambulatory patients with CHF, because the results herein
presented pertain to a population of outpatients with CHF,
mainly followed by cardiologists and speciﬁcally selected to
be enrolled in a clinical trial; and (4) detailed information
about the presence of obstructive sleep apnea, duration of
diabetes mellitus, use of different classes of oral hypo-
glycemic agents as well as follow-up data on fasting glucose
and HbA1c measurements were not available.
Table 3. Cox Regression Analysis of All-Cause Death Alone or in Combination With Cardiovascular Hospitalization in the Whole
Cohort of Patients With Chronic HF Enrolled in the GISSI-HF Trial
Variables
All-Cause Death
All-Cause Death or Cardiovascular Hospitalization (Combined
End Point)
Unadjusted HR Adjusted HR Unadjusted HR Adjusted HR
Non-DM Ref. Ref. Ref. Ref.
Pre-DM status (yes vs no) 0.93 [0.82–1.05] 0.93 [0.82–1.06] 0.94 [0.86–1.02] 0.94 [0.86–1.02]
DM status (yes vs no) 1.50 [1.35–1.67]* 1.43 [1.28–1.60]* 1.28 [1.19–1.38]* 1.23 [1.13–1.32]*
Sex (female vs male)  0.82 [0.73–0.93]*  0.93 [0.86–1.01]
NYHA functional class (III–IV vs I–II)  1.53 [1.39–1.68]*  1.33 [1.25–1.43]*
Age, y  1.05 [1.04–1.05]*  1.02 [1.01–1.03]*
Systolic blood pressure, mm Hg  0.99 [0.989–0.995]*  0.99 [0.990–0.994]*
Heart rate, bpm  1.01 [1.003–1.009]*  1.00 [0.999–1.003]
BMI, kg/m2  0.97 [0.96–0.98]*  0.99 [0.98–0.99]*
Smoking (yes vs no)  0.96 [0.82–1.11]  0.96 [0.87–1.06]
Hypertension (yes vs no)  0.90 [0.82–0.99]*  1.01 [0.95–1.08]
Atrial fibrillation/flutter (yes vs no)  1.21 [1.09–1.33]*  1.25 [1.17–1.34]*
COPD (yes vs no)  1.43 [1.30–1.58]*  1.24 [1.15–1.34]*
HF etiology (ischemic vs nonischemic)  1.22 [1.11–1.34]*  1.28 [1.20–1.37]*
LVEF (%)  0.98 [0.978–0.989]*  0.98 [0.978–0.986]*
Total cholesterol, mg/dL  0.99 [0.997–0.999]*  0.99 [0.998–1.000]*
Creatinine, mg/dL  1.34 [1.27–1.40]*  1.22 [1.17–1.27]*
Cohort size, n=6935; data are expressed as HR and 95% CI (in parenthesis). Ref., reference category. Continuous variables were included in the multivariable regression model as
continuous measures. BMI indicates body mass index; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; GISSI-HF, Gruppo Italiano per lo Studio della Sopravvivenza
nella Insufﬁcienza Cardiaca-Heart Failure; HF, heart failure; HR, hazard ratio; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
*Signiﬁcant (P < 0.05) associations.
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Table 4. Cox Regression Analysis of All-Cause Death Alone or in Combination With Cardiovascular Hospitalization in Patients With
Chronic HF and LVEF ≤40% Enrolled in the GISSI-HF Trial
Variables
All-Cause Death
All-Cause Death or Cardiovascular Hospitalization (Combined
End Point)
Unadjusted HR Adjusted HR Unadjusted HR Adjusted HR
Non-DM Ref. Ref. Ref. Ref.
Pre-DM status (yes vs no) 0.91 [0.80–1.04] 0.93 [0.82–1.07] 0.91 [0.84–1.00]* 0.93 [0.85–1.01]
DM status (yes vs no) 1.54 [1.37–1.72]* 1.45 [1.29–1.62]* 1.26 [1.17–1.36]* 1.21 [1.11–1.31]*
Sex (female vs male)  0.79 [0.69–0.90]*  0.90 [0.82–0.99]
NYHA functional class (III–IV vs I–II)  1.47 [1.33–1.63]*  1.28 [1.19–1.38]*
Age, y  1.04 [1.036–1.048]*  1.01 [1.009–1.016]*
Systolic blood pressure, mm Hg  0.99 [0.989–0.995]*  0.99 [0.990–0.994]*
Heart rate, bpm  1.01 [1.002–1.009]*  1.00 [0.999–1.004]
BMI, kg/m2  0.97 [0.96–0.98]*  0.99 [0.981–0.997]*
Smoking (yes vs no)  0.95 [0.82–1.11]  0.97 [0.88–1.07]
Hypertension (yes vs no)  0.92 [0.83–1.01]  1.01 [0.94–1.09]
Atrial fibrillation/flutter (yes vs no)  1.20 [1.08–1.33]*  1.24 [1.15–1.33]*
COPD (yes vs no)  1.43 [1.28–1.59]*  1.24 [1.14–1.34]*
HF etiology (ischemic vs nonischemic)  1.26 [1.14–1.39]*  1.33 [1.25–1.43]*
LVEF (%)  0.97 [0.962–0.977]*  0.97 [0.962–0.972]*
Total cholesterol, mg/dL  0.99 [0.997–0.999]*  0.99 [0.998–1.000]*
Creatinine, mg/dL  1.33 [1.26–1.40]*  1.22 [1.17–1.28]*
Cohort size, n=6283; data are expressed as HR and 95% CI (in parenthesis). Ref., reference category. Continuous variables were included in the multivariable regression model as
continuous measures. BMI indicates body mass index; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; GISSI-HF indicates Gruppo Italiano per lo Studio della
Sopravvivenza nella Insufﬁcienza Cardiaca-Heart Failure; HF, heart failure; HR, hazard ratio; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
*Signiﬁcant (P < 0.05) associations.
Table 5. Association Between HbA1c Tertiles at Baseline and Adverse Clinical Outcomes in a Subset of Patients With Chronic HF
Who Had Available HbA1c Measurements
Subgroup(s) Clinical Outcome(s)
HbA1c Tertiles
(%)
Events/
Patients
Rate Per 100 Patient-Years [95%
CI] Adjusted* HR [95% CI]
Patients with DM (n=2466) All-cause death ≤6.5 288/844 10.0 [8.9–11.2] Ref.
6.6 to 7.5 269/820 9.6 [8.5–10.8] 0.96 [0.81–1.14]
>7.5 286/802 10.6 [9.4–11.8] 1.21 [1.02–1.43]*
Combined end
point
≤6.5 525/844 18.2 [16.7–19.8] Ref.
6.6 to 7.5 517/820 18.4 [16.9–20.0] 0.99 [0.88–1.12]
>7.5 521/802 19.2 [17.7–21.0] 1.14 [1.01–1.29]*
Patients with Pre-DM or non-DM
(n=3232)
All-cause death ≤5.3 237/1102 5.7 [5.0–6.5] Ref.
5.4 to 5.8 272/1135 6.6 [5.8–7.4] 1.09 [0.92–1.30]
>5.8 248/995 7.0 [6.2–7.9] 1.07 [0.90–1.29]
Combined end
point
≤5.3 557/1102 13.4 [12.3–14.5] Ref.
5.4 to 5.8 601/1135 14.5 [13.4–15.7] 1.04 [0.93–1.17]
>5.8 562/995 15.9 [14.6–17.2] 1.10 [0.98–1.24]
Cohort size, n=5698 with available HbA1c measurements at baseline. Ref., reference category. In this analysis, patients with non-DM and pre-DM were combined into a single group. DM
indicates diabetes mellitus; HbA1c, hemoglobin A1c; HF, heart failure; HR, hazard ratio.
*Covariates for adjustment are the same of those reported in Table 3: sex, age, body mass index, heart rate, New York Heart Association functional class, systolic blood pressure, smoking,
hypertension, atrial ﬁbrillation/ﬂutter, chronic obstructive pulmonary disorder, ischemic heart failure etiology, left ventricular ejection fraction, serum total cholesterol, and creatinine levels.
*Signiﬁcant (P < 0.05) associations.
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In conclusion, the results of the GISSI-HF trial show that
the presence of known or previously undiagnosed DM was
independently associated with an increased risk of all-cause
death and cardiovascular hospitalization in ambulatory
patients with CHF over a median follow-up period of
3.9 years. Conversely, the rates of both clinical outcomes
were similar between patients with pre-DM and those without
DM. In an era in which there is increasing emphasis on
chronic disease preventive care as a strategy to contain
healthcare costs, our results further highlight the prognostic
value of DM and the need for therapies that improve survival
outcomes in patients with coexistent CHF and DM. As also
anticipated by the 2016 European Society of Cardiology
guidelines,12 the optimization of the individual treatment for
DM and other accompanying modiﬁable cardiovascular risk
factors in patients with HF needs a mindset change, from a
less “cardiocentric” approach to a more-comprehensive
clinical care in a multidisciplinary HF team.
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